Acquisition of Exclusive GSK Medications - MOMELOTINIB - 2026
About This Opportunity
TranslatedThis tender pertains to the acquisition of exclusive GSK medications, specifically focusing on MOMELOTINIB for the year 2026. The procurement aims to secure a reliable supply of this medication, which is crucial for treating specific medical conditions. Interested bidders are expected to demonstrate their capability in providing high-quality pharmaceutical products that meet regulatory standards. Key requirements include compliance with health regulations, proven experience in pharmaceutical supply, and the ability to deliver the medication within the specified timelines. The tender is open to qualified suppliers who can meet the necessary criteria and provide evidence of their capacity to fulfill the contract. The location for this procurement is not explicitly stated, but it is implied that it will serve healthcare institutions that require MOMELOTINIB. This tender represents an important opportunity for suppliers in the pharmaceutical sector to engage in a significant public health initiative, ensuring that essential medications are available for patient care. Bidders are encouraged to review the detailed specifications and requirements outlined in the tender documents to ensure a comprehensive proposal submission.
This is a supplies contract in the health and medical services, transport and logistics and trade and industry sectors, with a focus on Pharmaceuticals and Manufacturing. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 105,752.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThe tender titled "Aquisição de Medicamentos Exclusivos GSK - MOMELOTINIB - 2026" pertains to the procurement of exclusive medications from GSK, specifically the drug Momelotinib, and is located in Portugal. This initiative is part of public sector efforts to ensure the availability of essential pharmaceuticals within the healthcare system.
The contracting authority overseeing this procurement process is likely a public health entity tasked with managing and supplying medications to hospitals and clinics across Portugal. The tender aims to secure a reliable source of Momelotinib, which is indicated for specific therapeutic applications, potentially involving patient care for particular conditions.
In typical pharmaceutical tenders of this nature, requirements often include the provision of detailed technical specifications, compliance with regulatory standards, and evidence of good manufacturing practices. Suppliers may be asked to demonstrate their capacity for timely delivery and the ability to maintain consistent quality throughout the contract duration. Additionally, bidders are usually required to provide pricing details, terms of supply, and any necessary certifications to validate their credentials and compliance with both local and international regulations.
Potential bidders should be prepared to submit comprehensive proposals that not only meet the outlined specifications but also highlight their experience in pharmaceutical supply, commitment to sustainability, and ability to navigate the complexities of public sector procurement. This tender represents an important opportunity for pharmaceutical companies to contribute to the healthcare sector in Portugal while ensuring access to critical medications.
Data provenance
This notice is sourced from base_gov_pt and was originally published on February 16, 2026. Last refreshed 8 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Unidade Local de Saúde de Gaia/Espinho, EPE
Unidade Local de Saúde de Gaia/Espinho, EPE has issued 2,002 procurement notices on BidsFactory, including 5 currently open and 1,899 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Construction & Civil Works. All notices are published for Portugal. Notices are distributed via base_gov_pt and TED - Tenders Electronic Daily (EU). Most recent publication: June 18, 2026.
Frequently asked questions about this tender
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to GlaxoSmithKline-Prod.Farm.Ldª. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Unidade Local de Saúde de Gaia/Espinho, EPE in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €105,752. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.